All In Biotech

Drug Trial Radar · NCT07441694

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms

Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 218 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

218

Planned (sponsor's estimate)

Start

May 11, 2026

Primary completion

May 24, 2030

Study completion May 24, 2030

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
Mar 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.

Conditions

  • Myeloproliferative Neoplasms

Interventions

  • INCA036978Drug

    INCA036978 will be administered at protocol defined dose.

  • Standard disease-directed therapyDrug

    A standard disease-directed therapy will be administered according to Prescribing Information/SmPC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Dose Limiting Toxicities (DLT)s in Part 1Time frame: Up to 28 days
  2. Number of participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 2 years
  3. Number of participants with TEAEs leading to dose modification or discontinuationTime frame: Up to approximately 2 years

Locations

54 sites in 11 countries. Site status is shown where the registry gives one.

  • University of Alabama At Birmingham

    Birmingham, Alabama · Not yet recruiting

  • City of Hope-Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • Usc Norris Comprehensive Cancer Center

    Los Angeles, California · Not yet recruiting

  • UCLA Medical Hematology & Oncology

    Los Angeles, California · Not yet recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Not yet recruiting

  • University of Miami

    Miami, Florida · Not yet recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Not yet recruiting

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia · Recruiting

  • John Hopkins Hospital

    Baltimore, Maryland · Not yet recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Not yet recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Not yet recruiting

  • Mount Sinai School of Medicine

    New York, New York · Not yet recruiting

  • Weill Cornell Medicine

    New York, New York · Not yet recruiting

  • University of North Carolina At Chapel Hill

    Chapel Hill, North Carolina · Recruiting

  • Levine Cancer Institute

    Charlotte, North Carolina · Not yet recruiting

  • Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy

    Durham, North Carolina · Not yet recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Not yet recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • Tristar Bmt/Tcto

    Nashville, Tennessee · Recruiting

  • University of Texas M. D. Anderson Cancer Center

    Houston, Texas · Not yet recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah · Not yet recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Not yet recruiting

  • Concord General Repatriation Hospital

    Concord, New South Wales, Australia · Recruiting

  • Royal North Shore Hospital

    St Leonards, New South Wales, Australia · Recruiting

  • Icon Cancer Centre

    Auchenflower, Queensland, Australia · Recruiting

  • Epworth Health Care

    East Melbourne, Victoria, Australia · Recruiting

  • Linear Clinical Research

    Nedlands, Western Australia, Australia · Recruiting

  • Centre Hospitalier Universitaire (Chu) de Liege

    Liège, Belgium · Not yet recruiting

  • AZ DELTA

    Roeselare, Belgium · Not yet recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Recruiting

  • McGill University Jewish General Hospital

    Montreal, Quebec, Canada · Not yet recruiting

  • Francois-Xavier

    Bordeaux, France · Recruiting

  • Hospital Saint Louis

    Paris, France · Recruiting

  • Institut Gustave Roussy

    Villejuif, France · Recruiting

  • University Medical Center Rwth Aachen

    Aachen, Germany · Recruiting

  • Charite Universitaetsmedizin Berlin - Campus Charite Mitte

    Berlin, Germany · Recruiting

  • Universitatklinikum Freiburg

    Freiburg im Breisgau, Germany · Recruiting

  • Universitatsklinikum Halle (Saale)

    Halle, Germany · Recruiting

  • Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii

    Mainz, Germany · Not yet recruiting

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.